[팍스넷뉴스 민승기 기자] While there are signs of a resurgence of the Corona 19 virus, expectations for the expansion of global supply for Korea’s No. In particular, the industry predicted that Skycobi One would be able to compete sufficiently with existing vaccines as it was made with a synthetic antigen method with proven safety and can be stored at room temperature.
According to related industries on the 4th, the number of new corona19 patients recorded 10,000 for the last two days in a row. Even on weekends with relatively few tests, more than 10,000 confirmed cases came out. In the past two weeks, the number of new confirmed cases has risen from 6,000 to 7,000, but since last week it has risen to close to 10,000. In addition, experts predict that the COVID-19 resurgence will occur sooner than expected as the amount of travel increases due to the full-fledged summer vacation.
At one time, as the development of the COVID-19 vaccine was somewhat delayed, the industry evaluated that it ‘no longer has marketability’. However, as the possibility of a resurgence increases, the industry is expecting an increase in global supply.
Experts are paying attention to the fact that Skycobione is based on a ‘synthetic antigen’ method that has been used for a long time in existing vaccines such as influenza, hepatitis B, and cervical cancer vaccines and has proven safety and effectiveness. Their explanation is that it can create a differentiated market only for synthetic antigen vaccines, such as inducing inoculation of people who are resistant to the previously developed COVID-19 vaccine.
One of Skycobi One’s strong competitiveness is that it can be refrigerated at 2-8 degrees Celsius and can be stored for a long time. Because it can be distributed using the existing vaccine logistics network, accessibility can be secured even in underdeveloped countries.
SK Bioscience is also rushing to prepare to enter the global market as well as the domestic market. It is said that preliminary work is currently underway to obtain approval from European and British health authorities. At the same time, the World Health Organization (WHO) is pursuing an emergency use license. When the WHO’s emergency use license is granted, a contract to supply vaccines to underdeveloped countries will be discussed in earnest with the COVAX Facility. Although the supply of Skycobi One will vary according to future negotiations, it is expected that at least hundreds of millions of inoculations will be supplied to the world, including underdeveloped countries.
An official from the securities industry said, “The amount of supply and price may vary depending on the negotiations between SK Bioscience and Kobex Performance. “He said. He emphasized, “Since the synthetic antigen-type vaccine can be stored at room temperature, it can be supplied through the existing vaccine distribution network.
ⓒWe look at the market with new eyes. Unauthorized reproduction and distribution of Paxnet News is prohibited.
